major
etiolog
agent
common
cold
human
rhinovirus
hrv
caus
million
lost
work
school
day
annual
moreov
clinic
studi
prove
associ
harmless
upper
respiratori
tract
infect
sever
diseas
eg
sinus
asthma
chronic
obstruct
pulmonari
diseas
medicin
socioeconom
impact
hrv
infect
lack
antivir
drug
substanti
need
intens
antivir
research
common
structur
featur
approxim
hrv
serotyp
icosahedr
shape
capsid
form
ident
copi
viral
capsid
protein
capsid
protect
singlestrand
posit
sens
rna
genom
base
length
structur
well
nonstructur
protein
produc
viral
life
cycl
identifi
potenti
target
block
viral
replic
step
attach
entri
uncoat
rna
protein
synthesi
synthet
natur
compound
moreov
interferon
phytoceut
shown
protect
host
cell
known
inhibitor
hrv
replic
discov
result
empir
semiempir
screen
cell
cultur
structureact
relationship
studi
use
hit
optim
lead
structur
discoveri
increas
structur
insight
molecular
understand
viral
protein
one
hand
advent
innov
computerassist
technolog
hand
facilit
ration
access
discoveri
small
chemic
entiti
antirhinovir
antihrv
activ
review
summar
exist
structur
knowledg
hrv
ii
focu
mechan
antihrv
agent
synthet
natur
origin
iii
demonstr
strategi
effici
lead
structur
discoveri
human
rhinovirus
hrv
major
caus
upper
respiratori
tract
symptom
socal
common
cold
human
name
reflect
primari
site
infect
hrv
nonenvelop
icosahedr
virus
small
size
diamet
nm
pico
small
latin
consist
rna
genom
assign
famili
picornavirida
current
viru
famili
order
picornaviral
compris
eight
genera
enteroviru
hepatoviru
cardioviru
kobuviru
teschoviru
erboviru
aphthoviru
parechoviru
speci
multitud
serotyp
high
similar
genom
sequenc
genom
organ
fig
former
genera
rhinoviru
enteroviru
combin
recent
keep
exist
name
enteroviru
wwwpicornastudygroup
comtaxaspeciesspecieshtm
overview
current
taxonomi
picornavirus
pathogen
human
well
newli
propos
speci
hrv
given
tabl
present
genu
enteroviru
includ
four
approv
human
enteroviru
hev
speci
heva
b
c
two
approv
hrv
speci
hrva
b
www
picornastudygroupcomtaxaspeciesspecieshtm
sinc
global
distribut
highli
diverg
hrv
strain
report
base
result
sequenc
genom
phylogenet
analys
propos
strain
repres
new
hrv
speci
hrvc
propos
concern
new
potenti
hrvd
speci
publish
sequenc
analysi
known
hrv
genom
approv
newli
propos
speci
genu
enteroviru
share
homolog
averag
amino
acid
ident
precapsid
protein
well
differ
antigen
properti
provid
basi
divis
speci
serotyp
tabl
rhinoviru
serotyp
current
known
accord
current
approv
taxonomi
hrv
hank
belong
hrva
hrvb
genom
known
hrva
b
serotyp
well
sever
field
isol
hrva
b
c
sequenc
complet
virus
classifi
hrvc
could
grown
cell
cultur
phylogenet
analys
perform
partial
sequenc
well
whole
genom
recent
comprehens
analysi
known
hrv
genom
reveal
hrva
hrvc
share
common
ancestor
sister
group
hrvb
ii
hrvc
repres
third
speci
iii
basal
diverg
within
hrva
three
distinct
strain
led
propos
fourth
speci
hrvd
hrva
b
often
induc
mild
usual
selflimit
upper
respiratori
ill
human
character
nasal
stuffi
discharg
sneez
sore
throat
cough
convent
term
common
cold
common
cold
heterogen
group
diseas
caus
numer
virus
belong
sever
differ
famili
eg
rhinovirus
coronavirus
enterovirus
adenovirus
hrv
repres
common
etiolog
agent
worldwid
larg
number
distinct
strain
circul
year
moreov
famili
even
singl
specimen
multipl
hrv
serotyp
detect
simultan
use
rtpcr
cultur
shown
hrv
induc
upper
respiratori
tract
infect
adult
well
children
higher
incid
describ
septemb
novemb
april
may
year
perhap
geograph
area
spring
import
time
rhinoviru
transmiss
although
overal
rate
respiratori
ill
lower
summer
rhinovirus
frequent
isol
time
year
incid
invers
proport
age
age
year
children
antibodi
rhinovirus
addit
common
cold
hrv
also
involv
acut
otiti
media
children
moreov
data
support
caus
associ
sever
lower
respiratori
tract
infect
infant
elderli
person
immunocompromis
patient
accumul
studi
childhood
adult
asthma
shown
hrv
infect
also
trigger
exacerb
patient
asthma
chronic
obstruct
pulmonari
diseas
cystic
fibrosi
recent
discov
novel
rhinoviru
genotyp
hrvc
associ
commun
outbreak
influenzalik
acut
upper
respiratori
infect
sever
low
respiratori
tract
infect
infant
eg
febril
wheez
bronchiolyti
asthma
exacerb
peak
fall
winter
addit
presenc
hrvc
middl
ear
patient
acut
otiti
media
demonstr
hrv
spread
occur
mean
viruscontamin
respiratori
secret
contain
high
viru
concentr
besid
direct
handtohand
transmiss
smalland
largeparticl
aerosol
transmiss
rhinovirus
shown
children
import
vector
hrv
transmiss
famili
member
moreov
studi
natur
hrvinfect
adult
provid
evid
daili
activ
infect
peopl
lead
contamin
environment
surfac
hrv
eg
light
switch
telephon
dial
button
handset
viru
transfer
finger
healthi
individu
infect
viral
contamin
hand
play
import
role
transmiss
hrv
persontoperson
interrupt
step
viru
transmiss
present
potenti
target
intervent
experiment
prove
treatment
hand
iodin
salicyl
pyroglutam
acid
observ
experiment
induc
infect
normal
adult
volunt
help
understand
pathogenesi
hrv
infect
human
infecti
dose
rhinoviru
low
infect
rate
deposit
hrv
nasal
conjunctiv
mucosa
virus
transport
posterior
nasopharynx
mucociliari
action
epitheli
cell
specif
receptor
epitheli
cell
adenoid
area
use
bind
entri
alreadi
hr
intranas
inocul
infecti
viru
detect
viru
shed
peak
second
day
infect
decreas
rapidli
thereaft
small
amount
virus
discov
nasal
secret
week
infect
viru
andor
viral
rna
demonstr
upper
well
lower
respiratori
tract
use
situ
hybrid
arruda
et
al
detect
viral
rna
low
number
ciliat
cell
nasal
biopsi
nasopharynx
small
portion
virusposit
ciliat
well
noncili
cell
posit
viral
rna
papadopoulo
et
al
provid
evid
hrv
may
also
lytic
infect
human
bronchial
epitheli
cell
cell
cultur
well
experiment
infect
volunt
induc
product
agreement
result
hrv
rna
detect
children
adult
pneumonia
taken
togeth
result
natur
cold
studi
well
experiment
infect
human
volunt
clearli
demonstr
hrv
abl
replic
upper
well
lower
airway
hrv
infect
trigger
vasodil
increas
vascular
permeabl
nasal
mucosa
lead
nasal
obstruct
rhinorrhoea
mechan
still
incomplet
understood
histopatholog
chang
observ
nasal
biopsi
specimen
infect
person
led
suggest
clinic
symptom
primarili
caus
inflammatori
respons
host
viru
infect
cytopath
effect
cpe
hrv
result
immunolog
investig
suggest
modest
correl
concentr
nasal
secret
sever
symptom
upper
lower
hrvinduc
respiratori
tract
diseas
day
viru
challeng
concentr
significantli
greater
nasal
secret
experiment
infect
symptomat
subject
infect
asymptomat
shamchalleng
subject
propos
mediat
neutrophil
infiltr
observ
symptomat
infect
experiment
rhinoviru
infect
onset
symptom
eg
nasal
stuffi
discharg
sneez
cough
observ
hr
intranas
inocul
viru
contrast
rhinoviru
infect
adult
fever
found
children
upper
respiratori
tract
infect
symptom
children
adult
may
hoars
headach
malais
lethargi
sometim
viral
infect
accompani
bacteri
complic
lead
instanc
acut
otiti
media
infect
children
sinus
pneumonia
experiment
infect
also
use
studi
causat
rhinoviru
infect
asthma
well
copd
exacerb
shown
hrv
infect
enhanc
airway
reactiv
predispos
allerg
patient
develop
late
asthmat
reaction
rhinovir
cold
associ
increas
histamin
respons
accompani
bronchial
mucos
lymphocyt
eosinophil
infiltr
recent
studi
increas
hrvinduc
clinic
ill
sever
asthmat
compar
normal
subject
demonstr
strong
relationship
shown
viru
load
lower
airway
virusinduc
inflamm
asthma
exacerb
sever
result
studi
also
indic
augment
impair
immun
like
import
mechan
mallia
et
al
provid
evid
low
dose
experiment
rhinoviru
infect
patient
copd
induc
symptom
lung
function
chang
typic
acut
exacerb
copd
viral
replic
increas
proinflammatori
cytokin
respons
associ
symptomat
cold
increas
lower
respiratori
tract
symptom
reduct
forc
expiratori
volum
peak
expiratori
flow
rate
epidemiolog
data
patholog
hrv
infect
explain
high
medic
socioeconom
impact
million
children
adult
taken
ill
common
cold
everi
year
need
medic
consult
unabl
attend
school
go
work
direct
cost
includ
hospit
medic
fee
symptomat
treatment
moreov
exacerb
major
caus
asthma
copd
morbid
mortal
health
care
cost
associ
diseas
date
specif
drug
prevent
reduc
rhinoviru
infect
avail
common
cold
treat
symptomat
analges
decongest
antihistamin
antituss
antibiot
often
wrongli
prescrib
larg
number
circul
hrv
serotyp
treatment
specif
antivir
drug
consid
strike
vaccin
therefor
search
new
highli
activ
synthet
andor
natur
antihrv
compound
absolut
essenti
repres
import
area
antivir
research
antihrv
drug
would
broad
spectrum
activ
high
number
hrv
serotyp
ii
administ
earli
infect
demonstr
good
antivir
effect
fast
infect
kinet
iii
safe
broad
applic
million
peopl
iv
direct
highli
conserv
target
low
risk
resist
develop
due
high
error
rate
lack
proofread
abil
rna
polymeras
picornavirus
natur
drugresist
variant
may
exist
viru
popul
resist
virus
emerg
treatment
hiv
anoth
highli
variabl
rna
viru
risk
resist
develop
andor
select
resist
viru
variant
could
minim
appli
combin
drug
direct
differ
target
clinic
symptom
suggest
primarili
caus
inflammatori
respons
host
viru
infect
mediat
specif
cytokin
advantag
drug
combin
could
addit
immunesuppress
activ
knowledg
structur
compon
nonstructur
protein
necessari
viral
multipl
stage
viral
life
cycl
essenti
precondit
develop
measur
prevent
treat
hrv
infect
structur
hrv
particl
well
known
infecti
virion
consist
icosahedr
protein
shell
capsid
surround
protect
genom
singl
positivestrand
rna
molecul
approxim
nucleotid
organ
enteroviru
genom
shown
figur
viral
genom
rna
infecti
encod
singl
long
open
read
frame
flank
untransl
region
utr
end
small
viral
protein
vpg
coval
link
end
end
polyadenyl
like
cellular
messeng
rna
structur
compon
within
utr
eg
cloverleaf
intern
ribosom
entri
site
ire
utr
play
import
role
rna
replic
well
protein
synthesi
nucleotid
sequenc
region
within
structur
highli
conserv
among
enterovirus
blockad
could
significantli
inhibit
viral
replic
molecular
structur
determin
xray
crystallographi
result
show
viral
capsid
compos
protom
three
outer
structur
protein
interior
starshap
plateau
fivefold
axi
symmetri
surround
deep
depress
canyon
anoth
smaller
depress
threefold
axi
detect
moreov
hydrophob
pocket
found
beneath
canyon
floor
except
pocket
occupi
fatti
acid
socal
pocket
factor
host
cell
molecul
suggest
play
import
role
viral
life
cycl
provid
transient
stabil
capsid
movement
one
host
cell
anoth
outer
surfac
virion
contain
neutral
antigen
well
host
cell
bind
site
latter
allow
viru
attach
molecul
host
cell
membran
adsorpt
receptor
start
life
cycl
base
receptor
use
two
group
hrv
distinguish
major
hrv
serotyp
major
group
use
intercellular
adhes
receptor
virus
belong
minor
group
attach
low
densiti
lipoprotein
ldl
receptor
veryldl
vldl
receptor
ldlrrelat
protein
cell
whereat
multipl
receptor
involv
hrv
major
group
appli
canyon
attach
site
bind
contrast
ldl
receptor
minor
group
virus
bind
near
tip
fivefold
vertex
shown
util
sialyl
glycoprotein
cellular
receptor
furthermor
variant
well
wildtyp
use
heparan
sulphat
proteoglycan
cell
attach
addit
interact
rhinovirus
receptor
lead
viru
concentr
cell
surfac
induc
releas
pocket
factor
conform
chang
capsid
mediat
viral
entri
via
endocytosi
wherea
bind
directli
caus
uncoat
releas
rna
genom
capsid
ldlbound
minor
group
rhinovirus
trigger
acidif
endosom
phdepend
pathway
detail
knowledg
capsid
structur
function
well
virusreceptor
interact
offer
good
possibl
develop
antivir
drug
interfer
first
step
viral
life
cycl
adsorpt
well
uncoat
uncoat
rhinoviru
protein
synthes
translat
singl
open
read
frame
use
cellular
ribosom
result
polyprotein
approxim
kd
cleav
viral
proteas
pro
pro
final
product
structur
nonstrutur
protein
immedi
translat
first
proteinas
releas
polyprotein
selfcleavag
primari
cleavag
viral
polyprotein
mediat
pro
thereaft
pro
releas
precursor
autocatalyt
cleavag
next
pro
precursor
pro
process
protein
capsid
protein
nonstructur
protein
region
interestingli
pro
cleav
also
compon
translat
initi
factor
necessari
host
cell
protein
synthesi
pro
andor
pro
rna
polymeras
transcript
factor
tfiid
tfiic
ubf
therefor
effect
inhibit
pro
pro
would
inhibit
viru
replic
could
also
prevent
shutoff
cellular
protein
rna
synthesi
moreov
activ
site
proteinas
highli
conserv
among
enteroviru
serotyp
high
conserv
conjunct
import
role
viru
multipl
predestin
enzym
target
antivir
therapi
viral
rna
polymeras
pol
repres
anoth
import
nonstructur
protein
hrv
form
complex
cellular
viral
protein
rna
replic
complex
enzym
synthes
viral
minusstrand
rna
use
templat
strand
synthesi
genom
viral
rna
vpg
primer
negativea
well
positivestrand
rna
synthesi
negativestrand
positivestrand
rna
synthesi
stimul
pro
viral
accessori
protein
includ
besid
pol
protein
play
import
role
inhibit
viral
rna
synthesi
antivir
compound
summari
knowledg
structur
viral
capsid
proteas
polymeras
import
function
viral
life
cycl
predestin
protein
potenti
antihrv
target
hrv
grow
sever
human
primat
cell
express
minor
group
ldl
receptor
andor
major
group
receptor
human
cell
suscept
hrv
infect
includ
embryon
kidney
amnion
diploid
fibroblast
embryon
lung
tonsil
liver
intestin
skin
adult
fibroblast
line
aorta
gingiv
kb
hela
continu
cell
line
suscept
hela
cell
human
fibroblast
viru
infect
may
vari
hrv
multipl
also
occur
primari
human
airway
fibroblast
differenti
bronchial
epithelium
proport
infect
epitheli
cell
shown
enhanc
level
viral
product
detect
poorli
differenti
comparison
differenti
epitheli
cell
degre
viral
infect
correl
induct
cell
viru
growth
caus
typic
cpe
character
balloon
refract
granular
shrinkag
infect
cell
hrvinduc
cpe
infecti
viru
titer
viral
protein
express
rna
synthesi
chosen
paramet
evalu
antihrv
activ
compound
cellcultur
base
assay
sever
method
antivir
screen
hrv
plaqu
reduct
assay
tradit
perform
accept
gold
standard
antivir
test
howev
test
labori
time
consum
evalu
subject
therefor
suit
routin
antivir
test
replac
method
base
quantif
protect
virusinduc
cpe
drug
treatment
cpe
sampletr
untreat
cell
compar
light
microscopi
evalu
also
subject
anoth
object
approach
spectrophotometr
quantif
cpe
result
neutral
red
crystal
violet
uptak
assay
tetrazolium
dye
reduct
method
allow
excel
rapid
antivir
screen
larg
number
compound
use
small
amount
extract
natur
synthet
compound
activ
sampl
schedul
addit
test
use
assay
eg
viru
yield
plaqu
reduct
assay
studi
mechan
action
activ
potenti
antivir
drug
approv
vivo
high
degre
speciesspecif
variat
prevent
infect
major
group
hrv
practic
anim
model
absent
long
time
chimpanze
infect
sever
hrv
serotyp
without
develop
clinic
sign
hrv
induc
infect
rabbit
guinea
pig
weanl
mice
inject
hrv
differ
rout
one
minor
group
hrv
serotyp
adapt
grow
mous
fibroblast
use
mous
model
rhinoviru
infect
growth
could
demonstr
base
fact
ldl
receptor
famili
highli
conserv
human
mous
newcomb
et
al
examin
whether
anoth
minor
group
viru
may
infect
mous
airway
femal
mice
author
demonstr
hrv
serotyp
replic
induc
airway
inflamm
vivo
result
strongli
correspond
bartlett
et
al
establish
three
novel
mous
model
rhinoviru
infect
mice
first
model
balbc
mice
infect
second
model
transgen
balbc
mice
express
mousehuman
chimera
inocul
major
group
rhinovirusinduc
exacerb
allerg
airway
inflamm
mimick
third
model
due
lack
smallanim
model
hrv
infect
experiment
human
challeng
model
use
approv
effect
potenti
antivir
drug
control
condit
preclin
studi
volunt
experiment
inocul
variou
serotyp
eg
examin
efficaci
potenti
antivir
drug
standard
condit
exampl
result
studi
capsidbind
proteas
rna
synthesi
inhibitor
well
interferon
describ
follow
section
antivir
agent
inhibit
viru
attach
capsid
uncoat
protein
rna
synthesi
picornavirus
best
studi
focu
section
inhibit
viru
attach
andor
uncoat
interrupt
viral
life
cycl
begin
prevent
hrv
infect
option
prevent
earli
step
viral
life
cycl
includ
viru
neutral
hrvspecif
antibodi
ii
receptor
blockad
antibodi
direct
cellular
receptor
ldl
iii
solubl
receptor
molecul
iv
compound
interact
viral
capsid
high
number
serotyp
circul
often
parallel
applic
hrvspecif
antibodi
thought
promis
approach
prevent
therapi
rhinoviru
infect
contrast
antibodi
direct
cellular
receptor
solubl
receptor
molecul
major
minor
group
hrv
could
inhibit
hrv
serotyp
respect
therefor
strategi
prevent
virusreceptor
interact
receptor
antibodi
solubl
receptor
molecul
extens
evalu
vitro
well
vivo
antivir
activ
icamand
ldlspecif
antibodi
confirm
cell
cultur
furthermor
prophylact
effect
safeti
intranas
administ
rhinoviru
murin
antibodi
assess
two
doubleblind
placebocontrol
random
studi
volunt
experiment
inocul
result
toxic
relat
antibodi
applic
recogn
higher
dosag
mgsubject
rhinoviru
murin
receptor
antibodi
reduc
overal
infect
ill
rate
associ
day
delay
onset
viru
shed
cold
symptom
viral
titer
nasal
symptom
significantli
reduc
second
day
challeng
summari
monoclon
antibodi
cellular
demonstr
effect
enough
new
strategi
creation
multival
fab
fusion
protein
new
molecul
name
demonstr
better
avid
vitro
potenc
hrv
convent
mab
develop
nasal
spray
name
coldsol
antagon
virusreceptor
interact
consid
anoth
promis
way
prevent
hrv
attach
host
cell
solubl
form
fulli
truncat
ldl
vldlreceptor
concatem
exhibit
antivir
activ
major
minor
group
hrv
respect
cell
cultur
solubl
form
compet
receptor
bind
site
viru
capsid
hinder
earli
infect
event
entri
uncoat
directli
inactiv
hrv
due
format
empti
capsid
solubl
ldl
receptor
fragment
neutral
viral
infect
aggreg
concatem
third
ligand
bind
modul
vldlreceptor
lead
viral
aggreg
block
receptor
bind
site
possibl
inhibit
viral
uncoat
crosslink
viral
capsid
subunit
via
multimodul
bind
antivir
activ
truncat
solubl
form
prove
infect
chimpanze
random
doubleblind
placebocontrol
trial
safeti
efficaci
intranas
administr
tremacamra
solubl
experiment
cold
human
shown
develop
report
agent
option
prevent
viru
attach
describ
lowmolecularweight
compound
socal
capsidbind
agent
enter
small
hydrophob
pocket
within
viral
capsid
protein
beneath
icambind
canyon
hrv
zhang
et
al
show
drug
may
integr
matur
virus
diffus
well
progeni
virus
assembl
grown
presenc
pleconaril
higher
occup
occur
drug
introduc
alreadyassembl
virus
capsidbind
induc
conform
chang
canyon
hinder
virusreceptor
interact
prevent
attach
host
cell
addit
uncoat
hrv
serotyp
shown
inhibit
result
potenti
loss
flexibl
viral
capsid
drug
bind
contrast
capsidbind
compound
prevent
attach
result
xray
studi
show
drug
bind
hydrophob
pocket
replac
pocket
factor
induc
small
conform
chang
therefor
kim
et
al
suggest
observ
conform
chang
small
affect
receptor
bind
capsidbind
compound
prevent
attach
possess
pocket
factor
like
without
distinct
deform
pocket
result
compar
antivir
studi
differ
capsidbind
compound
hrv
repres
major
minor
group
reveal
correl
inhibit
adsorpt
receptor
group
antivir
group
reason
differ
mode
action
capsidbind
compound
relat
attach
inhibit
fulli
understood
taken
togeth
inhibit
rna
uncoat
found
investig
serotyp
drug
bind
independ
receptor
group
wherea
prevent
viru
attach
found
addit
mode
action
individu
virus
andor
drug
till
variou
potent
compound
belong
divers
chemic
class
describ
uncoat
inhibitor
give
impress
divers
structur
disoxaril
pleconaril
pirodavir
oxim
ether
isoxazol
deriv
compound
imidazol
deriv
sch
chalcon
ro
dichloroflavan
isoflavan
pyridin
deriv
mdl
phenoxybenzen
exhibit
potent
antihrv
activ
tabl
ii
shown
exampl
figur
inhibit
hrv
serotyp
coupl
also
affect
enterovirus
howev
vari
suscept
base
variabl
suscept
capsidbind
differ
length
hrv
serotyp
classifi
two
differ
group
b
sever
given
exampl
compound
also
clinic
test
studi
develop
clinic
effect
capsidbind
long
road
discoveri
clinic
effect
antihrv
drug
becom
appar
one
welldescrib
exampl
repres
discoveri
optim
capsidbind
sterl
winthrop
pharmaceut
group
socal
win
compound
first
inhibitor
origin
juvenil
hormon
mimet
demonstr
activ
determin
xray
structur
help
understand
compound
bind
site
viru
capsid
result
subsequ
xray
studi
hrvwin
compound
complex
reveal
locat
natur
bind
site
provid
inform
concern
interact
within
site
knowledg
use
optim
design
new
compound
optim
win
compound
exampl
disoxaril
pleconaril
fig
consist
methylisoxazol
ring
substitut
phenoxi
group
fivememb
heteroatom
ring
inhibit
broad
spectrum
rhinovirus
enterovirus
tabl
ii
first
broadspectrum
win
compound
disoxaril
win
test
clinic
trial
develop
crystallurea
human
volunt
treat
high
dose
well
low
bioavail
prohibit
subsequ
develop
thereaft
result
sar
qsar
analysi
use
enhanc
potenc
spectrum
activ
anoth
compound
win
clinic
test
effect
human
infect
moreov
rapidli
metabol
induc
revers
hepat
consequ
clinic
develop
stop
better
understand
pharmacokinet
properti
capsid
binder
synthet
chemistri
effort
led
discoveri
pleconaril
oral
bioavail
welltoler
capsidbind
inhibit
rhinoviru
well
variou
enteroviru
serotyp
schiff
et
al
publish
efficaci
pleconaril
experiment
induc
coxsackieviru
infect
human
phase
ii
placebocontrol
natur
cold
trial
drug
produc
moder
reduct
day
medium
time
elev
ill
compar
placebo
result
confirm
two
subsequ
pivot
studi
besid
moder
clinic
efficaci
studi
reveal
baselin
isol
suscept
pleconaril
develop
reduc
suscept
defin
increas
baselin
valu
subsequ
studi
relationship
pleconaril
suscept
clinic
outcom
treatment
common
cold
caus
rhinovirus
demonstr
base
drug
interact
margin
treatment
effect
possibl
transmiss
resist
virus
fda
approv
appli
oral
administr
pleconaril
treatment
common
cold
molecular
mechan
drug
interact
oral
given
pleconaril
shown
base
hepat
cytochrom
activ
reduc
advers
effect
sheringplough
licens
viropharma
complet
phase
ii
clinic
trial
intranas
formul
pleconaril
potenti
treatment
common
cold
highrisk
popul
result
publish
pyridazin
analogu
develop
janssen
research
foundat
repres
anoth
exampl
long
road
discoveri
clinic
effect
capsidbind
broadspectrum
activ
pirodavir
fig
tabl
ii
rhinovirus
publish
year
result
random
doubleblind
placebocontrol
trail
assess
therapeut
efficaci
intranas
pirodavir
natur
common
cold
describ
possibl
result
poor
water
solubl
rapid
hydrolysi
pirodavir
clinic
benefit
found
problem
ester
hydrolysi
resolv
develop
oxim
ether
analogu
pirodavir
biota
exampl
shown
figur
like
pirodavir
new
analogu
potent
inhibitor
rhinovirus
advantag
pirodavir
improv
bioavail
antivir
analogu
long
halflif
good
oral
bioavail
schedul
phase
ii
clinic
trial
result
yet
publish
summari
despit
extens
research
lead
discoveri
potent
antihrv
capsidbind
agent
approv
prevent
andor
therapi
rhinovirusinduc
diseas
far
nearli
conclus
drawn
proteas
inhibitor
pivot
role
viral
polyprotein
process
high
conserv
critic
amino
acid
pro
well
pro
repres
potenti
antihrv
target
result
cell
culturebas
assay
provid
evid
inhibit
hrv
replic
principl
possibl
exampl
process
polyprotein
prevent
pyrrolidin
dithiocarbam
treatment
virusinfect
hela
cell
contrast
enterovirus
pretreat
cell
monolay
differ
nitric
oxid
donor
lead
snitrosyl
pro
pro
neither
effect
viru
replic
hrvinduc
elabor
proteolyt
activ
pro
specif
inhibit
two
elastasespecif
inhibitor
antivir
peptid
repres
deriv
caspas
inhibitor
zvadfmk
homophthalimid
eg
fig
tabl
ii
describ
inhibitor
pro
well
pro
contrast
proteas
structureact
relationship
studi
report
hrv
proteas
moreov
proteas
accomplish
one
cleavag
hrv
polyprotein
proteas
perform
cleavag
elucid
crystal
structur
pro
comput
model
structur
featur
proteas
inhibitor
becam
possibl
furthermor
structurebas
design
use
develop
mechanismbas
inhibitor
proteas
potent
antivir
activ
multipl
hrv
serotyp
highli
activ
compound
incorpor
variou
michael
acceptor
moieti
irrevers
bind
pro
exhibit
activ
hela
cell
structureact
studi
perform
optim
proteas
inhibitor
effort
result
identif
highli
activ
antihrv
compound
rupintrivir
fig
tabl
ii
enter
clinic
trial
cell
cultur
inhibit
broad
spectrum
laboratori
hrv
well
clinic
isol
singlecycl
timeofaddit
assay
demonstr
antivir
activ
ad
hr
infect
inhibit
hrv
replic
strongli
correl
reduct
level
releas
cell
supernat
lead
suggest
agent
may
block
viru
replic
also
diminish
symptom
pharmacokinet
safeti
rupintrivir
prove
two
doubleblind
random
placebocontrol
studi
intranas
rupintrivir
administ
singl
dose
mg
everi
hr
six
time
per
day
day
safe
well
toler
three
doubl
blind
placebocontrol
clinic
trial
conduct
assess
rupintrivir
nasal
spray
solut
prevent
treatment
experiment
induc
rhinoviru
cold
healthi
volunt
rupintrivir
prophylaxi
reduc
proport
subject
posit
viral
cultur
viral
titer
decreas
frequenc
cold
drug
treatment
led
reduct
mean
total
daili
symptom
score
subject
receiv
rupintrivir
also
demonstr
significantli
lower
viral
titer
rna
level
placebotr
subject
day
day
respect
influenc
proport
subject
posit
viral
cultur
frequenc
cold
clinic
develop
termin
rupintrivir
act
subsequ
natur
infect
studi
patient
parallel
research
effort
oral
bioavail
inhibitor
tabl
ii
discov
like
rupintrivir
compound
irrevers
inhibitor
incorpor
michael
acceptor
moieti
form
coval
bond
proteas
activ
site
cystein
demonstr
antivir
activ
hrv
relat
picornavirus
test
phase
clinic
studi
compound
shown
safe
well
toler
accord
public
patick
clinic
develop
plan
compound
block
viral
rna
synthesi
replic
repres
anoth
site
chemotherapeut
interdict
shown
rhinovir
rna
target
sequencespecif
manner
deoxyribozym
morpholino
oligom
small
interf
ribonucl
acid
efficaci
latter
two
approach
confirm
cell
cultur
addit
chlorid
fig
tabl
ii
tabl
iii
pyrrolidin
dithiocarbam
fig
interf
rhinovir
rna
synthesi
inhibit
hrv
replic
cell
culturebas
assay
nucleosid
analog
ribavirin
fig
tabl
ii
inhibit
broad
spectrum
rna
well
dna
virus
act
also
hela
cell
cellular
inosin
monophosph
dehydrogenas
control
de
novo
synthesi
purin
nucleosid
repres
princip
target
mode
action
ribavirin
moreov
ribavirin
incorpor
picornaviru
rna
pair
equal
well
either
uracil
cytosin
induc
mutat
lethal
rna
virus
identifi
mechan
action
ribavirin
includ
inhibit
genom
rna
cap
enhanc
host
tcellmedi
immun
viral
infect
help
switch
host
tcell
phenotyp
type
type
anoth
compound
potent
antihrv
activ
vitro
enviroxim
fig
tabl
ii
benzimidazol
deriv
inhibit
viral
plu
strand
rna
synthesi
particular
protein
involv
initi
plu
strand
rna
synthesi
implic
like
target
drug
activ
howev
result
anoth
studi
suggest
enviroxim
target
complex
protein
andor
cellular
factor
exact
mechan
remain
studi
although
statist
signific
reduct
clinic
score
prophylact
studi
volunt
enviroxim
fail
experiment
induc
infect
clinic
studi
poor
bioavail
side
effect
attempt
overcom
mark
hydrophob
water
insolubl
toxic
wyde
et
al
incorpor
enviroxim
liposom
test
antihrv
activ
toxic
liposomeincorpor
enviroxim
cell
cultur
liposom
prepar
enviroxim
inhibit
effect
parent
compound
less
toxic
contrast
free
enviroxim
liposom
prepar
readili
success
deliv
smallparticl
aerosol
upper
lower
respiratori
tract
mice
anoth
attempt
overcom
disadvantag
enviroxim
sever
benzimidazol
well
nonbenzimidazol
analog
synthes
studi
even
though
compound
better
bioavail
could
administ
oral
none
compound
test
clinic
studi
besid
virusspecif
target
cellular
inhibitor
like
interferon
may
repres
therapeut
approach
among
activ
interferon
exhibit
antivir
activ
advantag
interferon
applic
includ
broad
spectrum
activ
low
risk
resist
develop
human
leukocyt
fibroblast
well
recombin
human
interferon
prevent
hrvinduc
cpe
cell
cultur
wherea
variat
sensit
observ
intranas
appli
recombin
interferon
interferon
b
shown
effect
human
provid
prophylact
experiment
natur
rhinoviru
cold
signific
reduct
ill
frequenc
mean
symptom
score
nasal
secret
weight
frequenc
viru
isol
observ
contrast
recombin
interferon
g
prevent
hrv
infect
ill
may
enhanc
symptom
littl
therapeut
effect
found
patient
common
cold
interferon
treatment
moreov
bloodting
mucu
nasal
bleed
describ
side
effect
combin
interferon
dichloroflavan
enviroxim
chalcon
produc
synergist
increas
antivir
activ
vitro
attempt
demonstr
synergi
antihrv
effect
recombin
human
rhuifn
enviroxim
volunt
fail
accord
author
main
reason
failur
may
rapid
remov
enviroxim
nose
given
intranas
impact
natur
product
natur
provid
astonish
pool
secondari
metabolit
biosynthes
live
organ
plant
fungi
protozoan
insect
anim
sourc
contrast
synthet
compound
natur
product
character
overwhelm
chemic
divers
previous
chemic
divers
space
two
group
evalu
respect
drug
substanc
feher
schmidt
shown
combinatori
compound
dens
popul
small
area
wherea
natur
product
cover
wider
rang
quit
similar
chemic
space
occupi
drug
substanc
author
accordingli
suggest
combinatori
librari
mimic
distribut
properti
natur
product
might
biolog
relev
one
may
assum
secondari
metabolit
evolv
reaction
target
receptor
relat
defenc
protect
attract
signal
adapt
process
enrich
metabolit
structur
divers
also
optim
druglik
metabol
trait
like
favor
pharmacokinet
properti
evolutionari
concept
give
pool
natur
product
greatest
sourc
scaffold
divers
molecul
biolog
relev
newman
cragg
analyz
number
drug
approv
circumstanti
especi
antiinfect
area
strongli
depend
natur
product
structur
deriv
natur
scaffold
antiinfect
includ
antivir
vaccin
launch
drug
far
major
categori
synthet
origin
vaccin
antivir
drug
approv
exclud
high
number
vaccin
biolog
small
antivir
molecul
base
nucleosid
structur
peptidomimet
classifi
total
synthet
drug
howev
till
neither
synthet
natur
deriv
antihrv
drug
substanc
approv
treatment
prevent
hrv
infect
intens
research
develop
effort
field
natur
product
reveal
sever
inhibitor
viral
attach
entri
inhibitor
viral
proteas
natur
sourc
efficaci
natur
product
reflect
statist
launch
drug
also
empir
knowledg
gain
centuri
success
applic
naturalbas
ethnomedicin
product
plant
culinari
herb
spice
phytochem
pharmacolog
work
perform
ethnomedicin
antihrv
mainli
plant
reveal
high
number
activ
metabolit
differ
chemic
class
eg
coumarin
flavonoid
alkaloid
quinon
terpenoid
polyphenol
polysaccharid
natur
product
includ
complex
extract
chemic
entiti
biosynthes
natur
unambigu
present
antihrv
natur
product
prior
import
first
distinguish
singl
chemic
entiti
natur
ie
isol
purifi
natur
compound
one
hand
natur
prepar
compris
hundr
thousand
constitu
mainli
secondari
metabolit
hand
natur
prepar
deriv
plant
might
also
label
botan
phytoceut
phytotherapeut
agent
multicompon
prepar
might
show
vari
profil
constitu
depend
use
speci
origin
collect
time
plant
part
extract
procedur
prepar
method
manufactur
process
mention
import
element
paramet
affect
final
product
term
qualit
quantit
composit
chemic
constitu
may
impact
biolog
activ
accordingli
studi
perform
phytochem
specifi
extract
nonstandard
prepar
often
suffer
irreproduc
incompar
result
wide
varieti
natur
prepar
show
act
therapeut
hrv
viral
infect
often
complementari
overlap
antivir
mechan
action
remedi
describ
ethnopharmacolog
sourc
hand
gener
usual
consist
simpli
prepar
natur
item
whose
chemic
composit
complex
mani
contain
secondari
metabolit
possibl
activ
principl
never
examin
chemic
biochem
use
modern
medic
knowledg
howev
compon
plant
medicin
stood
test
time
may
offer
clue
great
interest
medicin
chemist
clear
advantag
applic
product
absent
rel
low
toxic
due
usual
longterm
empir
trial
although
knowledg
immunopathogenesi
rvinduc
diseas
remain
limit
host
defens
function
airway
epithelium
play
import
role
innateimmun
respons
hrvinfect
host
cell
respond
product
mediat
antivir
activ
type
interferon
nitric
oxid
produc
cytokin
chemokin
influenc
subsequ
induc
innateand
specificimmun
respons
process
benefici
facilit
clearanc
viru
respiratori
tract
also
caus
immunopatholog
follow
hrvinfect
diseas
sever
depend
direct
harm
effect
viru
well
tissu
damag
result
host
antivir
immun
respons
accordingli
number
agent
phenomenolog
effect
common
cold
shown
exert
activ
field
regener
tissu
damag
direct
antihrv
effect
sever
herbal
remedi
consist
multitud
secondari
metabolit
differ
chemic
class
may
attribut
benefici
way
treatment
common
cold
reduc
symptom
sever
durat
due
immunemodul
antioxid
antiinflammatori
properti
besid
commonli
observ
bioactiv
natur
product
multicompon
mixtur
like
botan
often
show
overlap
symptomat
effect
well
synergist
andor
addit
properti
thu
challeng
endeavor
track
observ
phenomenolog
effect
complex
mixtur
molecular
level
follow
section
explor
signific
current
knowledg
select
botan
prevent
therapi
common
cold
question
clinic
evid
efficaci
constitu
least
chemic
class
involv
observ
antihrv
effect
involv
pharmacolog
target
cover
far
possibl
echinacea
prepar
includ
express
juic
aerial
part
well
extract
root
aerial
part
one
speci
genu
echinacea
e
angustifolia
e
purpurea
e
pallida
recogn
botan
prevent
treatment
common
cold
flu
account
second
topsel
herbal
product
usmarket
accordingli
echinacea
come
much
scientif
scrutini
high
number
studi
deal
effect
echinacea
prevent
treat
common
cold
clinic
trial
recent
review
woelkart
et
al
author
summar
find
metaanalys
regard
random
control
trial
evalu
cochran
databas
random
clinic
trial
analyz
shah
et
al
experiment
hrvinfect
studi
pool
schoop
et
al
sum
clinic
data
echinacea
far
fulli
consist
mainli
base
problem
inher
assess
efficaci
echinacea
prepar
lack
compar
avail
prepar
studi
design
outcom
nevertheless
metaanalys
show
evid
prepar
base
aerial
part
echinacea
purpurea
might
effect
earli
treatment
cold
adult
echinacea
show
decreas
odd
develop
common
cold
durat
cold
day
similarli
evalu
three
induc
rhinoviru
prevent
studi
reveal
odd
experienc
clinic
cold
higher
placebo
echinacea
step
molecular
level
sever
constitu
found
echinacea
speci
could
potenti
affect
symptom
common
cold
chemic
identifi
substanc
includ
polysaccharid
glycoprotein
caffeic
acid
deriv
especi
cichor
acid
echinacosid
lipophil
polyacetylen
alkamid
pharmacolog
studi
shown
cichor
acid
alkamid
glycoprotein
polysaccharid
possess
immunomodulatori
activ
addit
alkamid
report
exert
antiinflammatori
effect
also
cannabinomimet
properti
suggest
molecular
mode
action
echinacea
alkamid
immunomodulatori
agent
radun
et
al
show
echinacea
alkamid
exert
cannabinoid
type
receptordepend
independ
immunomodulatori
effect
cytokin
express
differ
echinacea
constitu
evalu
antioxid
effect
measur
inhibit
vitro
cu
ii
catalyz
oxid
human
lowdens
lipoprotein
therebi
major
caffeic
acid
deriv
cichor
acid
echinacosid
show
highest
antioxid
effect
even
higher
combin
natur
mixtur
alkamid
sharma
et
al
use
cytokin
antibodi
array
investig
chang
proinflammatori
cytokin
chemokin
releas
human
bronchial
epitheli
cell
expos
hrv
applic
two
chemic
character
echinacea
extract
show
revers
stimul
releas
numer
proinflammatori
cytokinerel
molecul
eg
cytokin
chemokin
eotaxin
similar
studi
echinacea
extract
rich
polysaccharid
anoth
rich
alkamid
caffeic
acid
deriv
well
abl
neutral
effect
hrvinfect
epitheli
cell
use
gene
express
analysi
studi
reveal
antihrv
benefit
echinacea
prepar
involv
multipl
immun
respons
signal
pathway
taken
togeth
numer
pharmacolog
find
literatur
potenti
echinacea
prepar
constitu
combat
prevent
common
cold
deduc
immun
modul
antiinflammatori
antioxid
properti
may
also
act
combin
event
rather
act
directli
hrv
garlic
clove
use
tradit
treat
number
infecti
diseas
howev
confirmatori
studi
publish
regard
tradit
antivir
use
clinic
effect
garlic
prevent
common
cold
investig
josl
publish
doubleblind
placebo
control
studi
assess
patient
treatment
period
allicincontain
garlic
supplement
common
cold
infect
symptom
record
daili
diari
patient
treatment
group
significantli
fewer
cold
patient
placebo
group
vs
also
longer
durat
symptom
vs
day
soon
garlic
chew
cut
press
main
ingredi
sulphur
contain
alliin
broken
enzym
alliinas
thiosulfin
allicin
steam
distil
allicin
transform
diallyl
disulfid
diallyl
trisulfid
respons
distinct
smell
garlic
allicin
transform
compound
eand
zajoen
found
fresh
garlic
lipophil
extract
investig
differ
garlic
extract
isol
number
differ
human
patholog
virus
weber
et
al
could
show
allicin
activ
virucid
compon
fresh
garlic
fresh
extract
result
direct
incub
assay
let
suggest
allicin
bind
viral
protein
capsid
lead
subsequ
inhibit
viral
adsorpt
penetr
although
garlic
thiosulfin
endow
signific
cytotox
antivir
effect
obtain
nontox
concentr
besid
direct
antihrv
effect
fresh
garlic
extract
allicin
number
human
immun
function
found
enhanc
vitro
aqueou
garlic
extract
polar
thiosulfin
fraction
north
america
panax
quinquefolium
ginseng
speci
indigen
canada
unit
state
popular
herbal
remedi
combat
stress
modul
natur
acquir
immun
respons
american
ginseng
root
extract
rich
polyfuranosylpyranosylsaccharid
found
efficaci
prevent
upper
respiratori
infect
immunocompet
healthi
adult
random
doubleblind
placebo
control
trial
mg
proprietari
american
ginseng
root
extract
given
communitydwel
elderli
adult
age
year
twice
day
cold
flu
season
period
month
one
month
studi
particip
receiv
influenza
vaccin
first
two
month
signific
differ
durat
incid
observ
compar
placebo
howev
last
two
month
significantli
fewer
subject
ginseng
group
report
acut
respiratori
syndrom
placebo
group
vs
addit
durat
respiratori
symptom
reduc
ginseng
group
similarli
arrang
trial
healthi
adult
age
year
histori
least
two
cold
previou
year
commenc
month
studi
begin
cold
flu
season
receiv
two
mg
capsul
daili
standard
american
ginseng
root
extract
placebo
outcom
measur
number
cold
includ
symptom
sever
total
number
symptomat
day
therapeut
effect
report
regard
symptom
sever
fewer
symptom
day
lower
ginseng
group
placebo
group
phase
ii
random
control
trial
dose
schedul
american
ginseng
root
extract
rich
polyfuranosylpyranosylsaccharid
evalu
safeti
toler
efficaci
pediatr
popul
alreadi
suffer
upper
respiratori
tract
infect
result
show
seriou
advers
event
good
toler
ginseng
dose
howev
frequenc
sever
symptom
significantli
differ
among
three
treatment
group
ie
standard
dose
low
dose
placebo
promin
constitu
genu
panax
triterpen
saponin
ginsenosid
known
numer
pharmacolog
activ
anticanc
antidiabet
antivir
antiatherosclerosi
effect
compound
chemic
class
show
respons
immunostimul
activ
ginseng
hand
efficaci
polysacchariderich
extract
american
ginseng
compar
extract
rich
ginsenosid
system
gutassoci
immun
function
author
studi
investig
lymphocyt
isol
spleen
mesenter
lymph
node
peyer
patch
immun
cell
proport
cytokin
product
spraguedawley
rat
could
show
polysacchariderich
ginseng
extract
modifi
rat
system
immun
respons
affect
gutassoci
immun
manner
distinct
ginsenosidecontain
extract
american
ginseng
direct
antivir
activ
ginseng
constitu
could
attest
polysaccharid
rotaviru
infect
cell
triterpen
saponin
howev
exhibit
rotaviru
infectioninhibitori
activ
studi
moder
vitro
virucid
effect
id
mm
ginseng
saponin
chikusetsusaponin
iii
herp
simplex
viru
type
detect
fukushima
et
al
compound
exhibit
intracellular
inhibitori
activ
could
margin
affect
viral
protein
postinfect
ancient
chines
formula
buzhongyiqitang
japanes
name
hochuekkito
tradit
herbal
medicin
china
japan
compos
ten
speci
medicin
plant
name
astragali
radix
atractylodi
lancea
rhizoma
ginseng
radix
angelica
radix
bupleuri
radix
zizyphi
fructu
aurantii
nobili
pericarpium
glycyrrhiza
radix
cimicifuga
rhizoma
zingiberi
rhizoma
formula
report
variou
immunomodulatori
antiinflammatori
activ
yamaya
et
al
recent
investig
effect
hochuekkito
cultur
human
airway
epitheli
cell
infect
output
viru
associ
level
viral
rna
product
cytokin
acid
endosom
cell
measur
airway
epitheli
cell
hochuekkito
abl
decreas
viru
output
suscept
hrv
infect
decreas
block
entri
viral
rna
cytoplasm
endosom
glycyrrhizin
major
compon
one
herbal
ingredi
hochuekkito
ie
glycyrrhiza
glabra
abl
reduc
supernat
viru
titer
dosedepend
maximum
effect
mm
howev
clinic
trial
repres
number
subject
publish
far
human
rhinoviru
k
umckaloabo
pelargonium
sidoid
p
sidoid
p
reniform
form
origin
popular
drug
umckaloabo
herbal
remedi
south
africa
found
entranc
western
medicin
mainli
aqueou
ethanol
root
extract
p
sidoid
treatment
infect
respiratori
tract
efficaci
umckaloabo
compar
placebo
evalu
adult
suffer
common
cold
lizogub
et
al
appli
herbal
prepar
well
toler
patient
studi
demonstr
weak
efficaci
umckaloabo
compar
placebo
day
day
howev
p
sidoid
extract
significantli
reduc
sever
symptom
shorten
durat
common
cold
compar
placebo
recent
timmer
et
al
select
random
control
trial
examin
efficaci
p
sidoid
prepar
treatment
variou
acut
respiratori
infect
analyz
efficaci
safeti
author
conclud
umckaloabo
may
effect
allevi
symptom
acut
rhinosinus
common
cold
adult
may
effect
reliev
symptom
acut
bronchiti
adult
children
sinus
adult
reliabl
data
treatment
acut
respiratori
infect
howev
obtain
identif
metabolit
umckaloabo
reveal
high
number
differ
chemic
class
phenol
cinnam
acid
tannin
flavonoid
coumarin
antibacteri
activ
umckaloabo
differ
pathogen
report
phenol
coumarin
tannin
identifi
contribut
moder
antibacteri
activ
howev
explain
effect
whole
extract
review
kolodziej
addit
p
sidoid
extract
report
significantli
activ
nonspecif
immun
system
induct
tnf
noreleas
ifnlik
activ
effect
assum
contribut
controversi
discuss
potenti
p
sidoid
extract
treatment
upper
respiratori
tract
infect
one
studi
report
direct
antivir
effect
ie
clear
dosedepend
antiherp
simplex
viru
acit
aqueou
root
extract
p
sidoid
pharmacolog
studi
need
elucid
potenti
direct
antihrv
properti
umckaloaba
constitu
carrageenan
mixtur
differ
polysaccharid
mainli
extract
red
seawe
extens
use
food
cosmet
pharmaceut
industri
thicken
gell
agent
previous
shown
antivir
efficaci
sever
virus
recent
publish
studi
lambda
kappa
iotacarrageenan
investig
antihrv
inhibit
potenti
concentr
mgml
iotacarragenan
sulphat
polysaccharid
abl
fulli
inhibit
virusinduc
cell
death
infect
hela
cell
base
studi
grassauer
et
al
conclud
iotacarrageenan
effect
differ
hrvserotyp
primari
human
epitheli
cell
hypothes
author
iotacarrageenan
might
creat
hostil
environ
hrv
therebi
block
viral
entri
replic
safe
applic
prove
vitro
efficaci
iotacarrageenan
deserv
consider
candid
clinic
trial
prevent
therapi
hrvinduc
common
cold
level
knowledg
impact
six
botan
hrvinfect
discuss
differ
heterogen
best
studi
herbal
remedi
associ
common
cold
ie
echinacea
showcas
innat
problem
connect
multicompon
mixtur
start
late
nineti
till
june
origin
articl
publish
topic
tri
elucid
question
concern
efficaci
molecular
mechan
bioactiv
ingredi
echinacea
although
evid
provid
effect
extract
chemic
class
well
welldefin
constitu
specif
target
pathway
find
deduc
common
denomin
result
clinic
trial
often
suffer
lack
compar
use
differ
studi
design
outcom
measur
overal
applic
differ
prepar
proper
qualiti
analysi
character
prepar
investig
mandatori
follow
recommend
guidelin
report
clinic
trial
herbal
medicin
underlin
section
chemic
complex
natur
prepar
might
benefici
term
synergist
addit
overlap
effect
caus
multitud
evolutionari
trim
metabolit
may
attribut
modul
multitarget
effect
side
exactli
fact
hardli
compat
proper
assign
activ
defin
chemic
entiti
accord
western
medic
practis
contrast
singl
compound
synthet
natur
base
chemistri
botan
complex
also
vari
analyt
profil
term
pharmacolog
profil
investig
sampl
differ
substanti
accordingli
quantit
qualit
comparison
differ
studi
result
botan
far
complex
perform
pure
singl
compound
may
also
explain
littl
emphasi
pharmaceut
industri
put
develop
even
promis
natur
prepar
gener
search
potent
select
nontox
compound
might
develop
drug
substanc
multidisciplinari
timeand
costconsum
process
therefor
strategi
targetori
discoveri
leadstructur
either
natur
synthesi
high
demand
discuss
follow
section
provid
exampl
antihrv
research
alreadi
mention
natur
provid
extrem
rich
pool
bioactiv
natur
product
howev
challeng
endeavor
find
exactli
compound
show
activ
focus
target
natur
product
research
hint
folk
medicin
valuabl
start
point
dig
lead
structur
certain
interest
major
activ
principl
higher
plant
discov
result
ethnopharmacolog
direct
pharmacognost
research
oral
written
indic
benefici
applic
natur
materi
first
need
critic
evalu
select
correct
materi
medicin
prepar
kind
applic
overal
pharmacolog
profil
ration
critic
often
anecdot
efficaci
tradit
medicin
mandatori
attitud
avoid
overinterpret
handeddown
inform
case
pretend
antihrv
remedi
report
biolog
efficaci
obvious
suffer
restrict
respiratori
diseas
might
caus
panel
bacteri
viral
infect
thu
approv
remedi
may
affect
microb
show
immun
modul
even
antiinflammatori
effect
combin
holist
access
innat
charact
ethnopharmacolog
need
track
specif
involv
target
recent
publish
studi
focus
discoveri
hrvcapsid
binder
natur
use
pharmacophorebas
virtual
screen
ethnopharmacolog
bias
databas
secondari
metabolit
predict
act
capsidbind
inhibitor
hrv
depth
phytochem
pharmacolog
investig
mandatori
focu
one
promis
natur
materi
thu
consult
ethnobotan
sourc
materia
medica
written
pedaniu
dioscorid
st
centuri
ad
treatis
consist
five
book
compris
drug
deriv
miner
anim
major
plant
repres
great
repositori
botan
medic
pharmacolog
lore
scrutin
natur
materi
underli
obtain
virtual
hit
came
across
asafetida
gum
resin
gain
root
varieti
foulsmel
ferula
speci
apiacea
famili
base
descript
given
materia
medica
strong
evid
juic
ie
resin
popular
ancient
silphion
origin
media
syria
correspond
asafetida
book
iii
cap
yield
incis
root
stalk
frequent
mix
sagapenon
ie
resin
f
persica
willd
book
iii
cap
report
effect
context
upper
respiratori
diseas
eg
chronic
harsh
throat
clear
voic
shrink
uvula
suitabl
cough
pleurisi
chest
pain
sagapenon
describ
follow
clear
thick
matter
lung
given
chill
descript
final
help
priorit
virtual
hit
report
constitu
asafetida
pharmacolog
investig
asafetida
constitu
farnesiferol
b
c
fig
tabl
iii
reveal
distinct
effect
low
micromolar
rang
use
cpe
inhibitori
assay
result
studi
provid
rational
ancient
usag
asafetida
upper
respiratori
tract
infect
hand
tradit
manifest
evid
asafetida
treatment
common
cold
symptom
substanti
help
select
plant
materi
search
antihrv
capsid
binder
typic
ethnopharmacolog
base
discoveri
activ
antihrv
extract
follow
bioassay
guid
fraction
isol
constitu
respons
extract
bioactiv
concept
bioassayguid
approach
fraction
accompani
simultan
detect
activ
separ
step
result
continu
enrich
final
isol
activ
ingredi
way
larg
number
antihrv
agent
natur
sourc
alreadi
discov
sempl
et
al
investig
activ
principl
asteracea
plant
pterocaulon
sphacelatum
use
tradit
medicin
aborigin
peopl
australia
favor
treatment
respiratori
infect
especi
cold
mean
antivir
activityguid
fraction
measur
poliovirusinduc
cpe
assay
author
identifi
flavonoid
trihydroxyflavon
ie
chrysosplenol
c
fig
tabl
iii
potent
specif
inhibitor
picornavir
replic
fig
tabl
iii
also
isol
major
constitu
ethanol
extract
p
sphacelatum
show
activ
polioviru
interestingli
coumarin
exhibit
signific
effect
cpe
assay
recent
perform
virtual
parallel
screen
studi
perform
laboratori
contrast
isol
coumarin
chrysosplenol
c
alreadi
known
member
repres
potent
specif
inhibitor
picornavir
especi
rhinovir
replic
vanden
bergh
haemer
vlietinck
provid
profound
survey
antivir
agent
higher
plant
demonstr
impact
ethnobotan
knowledg
search
antivir
compound
african
medicin
plant
select
investig
plant
speci
mainli
base
upon
use
treatment
viral
diseas
african
tradit
healer
antivir
activ
differ
plant
speci
belong
famili
investig
thereof
speci
exhibit
promin
antivir
properti
one
test
virus
pronounc
activ
picornavirus
record
within
genu
euphorbia
compound
detect
antivir
constitu
respect
extract
identifi
deriv
especi
quercetin
kaempferol
fig
tabl
iii
show
signific
cytotox
highli
activ
tissu
cultur
human
picornavirus
tissu
cultur
cell
infect
differ
picornavirus
among
also
hrv
cpe
observ
cell
treat
mgml
select
natur
materi
base
ethnopharmacolog
profound
rational
lead
structur
discoveri
highli
superior
random
select
howev
rare
appli
marin
organ
fungi
microb
although
organ
esteem
highli
valuabl
sourc
bioactiv
metabolit
hardli
record
folk
medicin
given
mediums
activ
screen
use
robust
cellbas
vitroassay
reason
effort
time
cost
strategi
get
first
insight
antivir
activ
extract
fraction
compound
synthesi
natur
discoveri
novel
natur
base
hrv
inhibitor
singh
et
al
use
small
peptid
contain
qg
scissil
bond
substrat
vitro
screen
extract
author
isol
novel
benzoisochromanquinon
thysanon
fig
tabl
iii
extract
fungu
thysanophora
penicilloid
potent
hrv
inhibitori
activ
continu
screen
reveal
pronounc
hrv
inhibitori
activ
extract
chines
herb
polygonum
cuspidatum
bioassayguid
fraction
fig
tabl
iii
naphthoquinon
ic
valu
mm
isol
plant
materi
total
synthes
natur
compound
analogu
allow
structureact
relationship
particularli
comparison
activ
orthov
paraquinon
measur
select
compound
seri
cystein
proteas
hrv
compound
evalu
papain
simpl
fig
tabl
iii
activ
compound
seri
show
ic
valu
mm
distinctli
higher
degre
select
cpe
reduct
assay
appli
identif
raoulic
acid
bicycl
terpen
acid
fig
tabl
iii
isol
raoulia
australi
asteracea
raoulic
acid
exert
antivir
activ
coxsacki
viru
enteroviru
ic
valu
submicromolar
rang
activ
record
influenza
b
virus
cours
systemat
screen
microbi
natur
product
antihrv
activ
ishitsuka
et
al
identifi
fig
tabl
iii
leav
chines
medicin
plant
agastach
rugosa
lamiacea
natur
compound
high
activ
picornavirus
except
mengoviru
author
synthes
oral
activ
perform
investig
tissu
cultur
mice
determin
compound
mode
action
assum
process
viral
replic
thu
locat
viral
uncoat
initi
viral
rna
synthesi
activ
flavan
fig
tabl
iii
discov
serendipit
screen
program
use
plaqu
inhibit
assay
base
result
bauer
et
al
synthes
fig
tabl
ii
reveal
activ
number
hrv
serotyp
rang
mm
soon
activ
lead
compound
identifi
utmost
import
scrutin
deriv
activ
obtain
insight
chemic
requir
mandatori
focus
biolog
activ
ii
improv
compound
pharmacolog
profil
term
potenc
select
cytotox
etc
iii
improv
bioavail
nonphenol
aporphin
alkaloid
glaucin
promin
constitu
aerial
part
gaucium
flavum
papaveravea
recent
publish
studi
spasova
et
al
investig
antivir
potenti
glaucin
fig
tabl
iii
glaucin
deriv
semisynthes
cinnamoyland
hydroxycinnamoyl
amid
besid
antioxid
potenti
newli
synthes
compound
exert
antivir
activ
replic
best
antihrv
activ
observ
oxoglaucin
fig
tabl
iii
ic
tabl
iii
ic
mm
si
ic
mm
si
respect
earli
find
antihrv
activ
natur
deriv
inspir
chemist
pharmacologist
synthesi
pharmacolog
evalu
deriv
thereof
decor
variou
substitut
pattern
sever
report
publish
last
two
decad
review
find
antivir
flavonoid
research
investig
antivir
activ
wide
varieti
natur
occur
flavonoid
tsuchiya
et
al
found
chrysosplenol
b
c
fig
tabl
iii
contain
chrysosplenium
plant
axillarin
fig
tabl
iii
potent
antihrv
agent
base
find
flavon
skeleton
decor
methoxi
group
posit
group
reveal
mandatori
antihrv
activ
seri
antipicornavir
deriv
synthes
de
meyer
et
al
order
establish
structureact
relationship
therebi
differ
substitut
pattern
are
system
methyl
hydroxi
methoxi
halo
nitro
amino
perform
activ
polio
hrv
compar
natur
occur
flavonoid
import
hydroxylgroup
confirm
investig
differ
deriv
lack
featur
result
show
monosubstitut
are
less
activ
correspond
compound
polysubstitut
are
within
test
seri
compound
emerg
noncytotox
also
potent
substanc
antivir
test
system
lowest
concentr
compound
protect
cell
cpe
hrv
serotyp
rang
mgml
contrast
quercetin
flavon
also
report
mutagen
properti
measur
mgplate
shortterm
microbi
assay
mechan
studi
perform
shown
interfer
earli
stage
viral
rna
synthesi
induct
resist
observ
contrast
mode
action
antihrv
chalcon
flavan
report
interact
directli
specif
site
viral
capsid
protein
therebi
prevent
uncoat
consequ
liber
viral
rna
due
antihrv
potenc
low
toxic
promis
bioavail
dichloroflavan
evalu
protect
efficaci
experiment
hrvinfect
two
clinic
doubleblind
placebocontrol
trial
howev
drug
candid
fail
either
administ
oral
intranas
unfortun
till
clinic
trial
evalu
efficaci
common
cold
perform
common
idea
comput
approach
extract
knowledg
less
larg
set
data
order
make
predict
new
event
within
lead
discoveri
process
comput
approach
virtual
screen
dock
quantit
structureact
relationship
larg
enhanc
impact
comput
chemistri
nowaday
chemoinformat
play
predomin
role
drug
research
key
goal
use
method
reduc
overal
cost
associ
discoveri
develop
new
drug
identifi
promis
candid
focu
experiment
effort
number
book
review
impact
comput
chemistri
lead
structur
determin
highlight
effort
gener
silico
method
divid
ligandbas
approach
reli
known
activ
compound
base
physicochem
properti
crucial
biolog
affin
activ
predict
extrapol
notyet
test
substanc
eg
machin
learn
techniqu
classic
quantit
structureact
relationship
qsar
ligandbas
approach
invalu
tool
case
structur
inform
pharmacolog
target
avail
ii
hand
structurebas
approach
use
experiment
determin
structur
target
molecular
dock
structurebas
pharmacophor
model
virtual
screen
method
allow
gain
insight
proteinligand
interact
experiment
determin
static
level
howev
consid
flexibl
uniqu
platform
contain
coordin
experiment
solv
protein
structur
xray
crystallographi
nmr
protein
data
bank
pdb
current
compris
structur
biomolecul
proteinligand
complex
addit
sever
pdbrelat
web
servic
tool
enabl
use
pdbportal
rich
divers
inform
servic
student
scientist
particularli
earli
stage
drug
develop
lead
discoveri
lead
optim
comput
approach
allow
targetori
ration
proceed
thu
may
substanti
help
maxim
success
rate
recent
publish
review
impact
computerassist
approach
antivir
research
thoroughli
describ
underli
silico
techniqu
highlight
benefit
comput
approach
discoveri
antivir
lead
structur
antihrv
research
capsid
protein
proteas
reveal
promis
target
describ
inhibitor
assum
major
impact
treatment
hrvinfect
addit
target
structur
elucid
potent
ligand
known
well
fact
enabl
perform
sensibl
computerassist
approach
ligandand
structurebas
studi
use
silico
approach
discoveri
potenti
antihrv
agent
focus
mention
target
report
follow
paragraph
compound
act
potenti
hrvcapsid
binder
classic
qsar
qsar
studi
perform
classic
qsar
relationship
calcul
properti
deriv
chemic
structur
measur
biolog
activ
explor
statist
qsar
techniqu
aim
deriv
correl
turn
activ
predict
base
spatial
arrang
chemic
properti
atom
appli
qsar
techniqu
comfa
compar
molecular
field
analysi
statist
model
deriv
visual
colorcod
contour
around
molecul
therein
spot
indic
electrostat
properti
spatial
arrang
favor
biolog
activ
studi
diana
et
al
artico
et
al
verma
et
al
qsar
techniqu
help
one
hand
analyz
ration
structur
featur
activ
compound
essenti
interact
hrv
canyon
bind
pocket
hand
search
new
class
capsid
binder
thu
narrow
synthet
challeng
specif
antihrv
agent
respect
investig
hydrophob
found
one
import
determin
substanc
activ
qsar
combin
simplex
represent
molecular
structur
appli
kuzmin
et
al
base
select
index
cc
ic
inhibitori
concentr
set
biphenyloxi
propyl
isoxazol
deriv
basi
qsar
analysi
comput
design
three
new
isoxazol
high
activ
predict
select
synthes
reveal
strong
coincid
experiment
predict
antihrv
activ
select
index
termin
benzen
substitu
neg
electrostat
potenti
molecul
length
approxim
suggest
mandatori
featur
within
chemic
class
inhibitori
activ
hrvserotyp
show
high
level
conserv
proteas
bind
site
sequenc
align
secondari
structur
predict
suggest
overal
architectur
mechan
proteas
correl
cellular
cysteinand
serin
proteas
chymotrypsin
trypsin
ident
among
proteas
differ
famili
howev
modest
provid
space
develop
specif
inhibitor
proteas
recent
publish
review
select
inhibitor
picornaviru
replic
de
palma
et
al
summar
current
known
chemic
structur
act
peptid
nonpeptid
inhibitor
viral
target
reich
et
al
use
hrv
proteas
cocryst
structur
inform
ration
targetori
synthesi
hrv
proteas
inhibitor
class
substitut
benzamid
activ
data
subsequ
crystallograph
studi
point
import
requir
inhibit
proteas
similarli
maugeri
et
al
use
structurebas
approach
perform
dock
studi
base
proteas
crystal
structur
virtual
librari
consist
benzamid
deriv
quantummechan
calcul
propos
substitu
promis
biolog
activ
workflow
guid
design
synthesi
substanc
virtual
assum
act
substrat
analogu
synthesi
compound
biolog
test
confirm
underli
hypothesi
quantit
molecular
model
studi
perform
better
defin
predict
interact
bicycl
deriv
show
irrevers
inhibitor
proteas
studi
molecular
mechan
simul
evalu
chemic
rate
coval
bond
format
free
energi
calcul
combin
crystallograph
studi
appli
explain
differ
activ
irrevers
peptidomimet
inhibitor
data
use
basi
optim
compound
recent
studi
perform
kuo
et
al
compound
subject
high
troughput
screen
search
novel
inhibitor
proteas
picornaviru
coronaviru
respect
five
nonpeptid
identifi
ic
valu
mm
sever
acut
respiratori
syndromecoronaviru
one
molecul
found
addit
inhibit
proteas
coxsackieviru
enteroviru
rhinoviru
compound
id
contain
dihydropyrazol
ring
decor
two
phenyl
group
lengthi
nbutylbenzimidazolylaminotoluen
use
start
point
select
four
analog
show
ic
valu
rang
mm
test
viral
proteas
mean
dockingbas
comput
model
author
tri
ration
bind
discrep
respons
individu
common
proteas
inhibitor
thu
provid
ration
base
develop
nonpeptid
multiplefunct
inhibitor
coronavirus
piciornavirus
antihrv
research
first
applic
scenario
conduct
use
pharmacophor
model
accord
offici
iupac
definit
wermuth
et
al
pharmacophor
describ
arrang
steric
electron
featur
necessari
trigger
block
biolog
respons
pharmacophor
repres
threedimension
chemic
featur
includ
hydrogen
bond
donor
acceptor
aromat
ring
hydrophob
group
well
posit
neg
ionis
moieti
addit
shape
ligand
repres
shape
featur
essenti
describ
van
der
waal
radii
ligand
atom
pharmacophor
concept
proven
success
ration
structureact
relationship
also
larg
impact
develop
appropri
effici
virtual
screen
steindl
et
al
elabor
ligandand
structurebas
pharmacophor
model
implement
essenti
featur
coval
bind
cystein
activ
site
proteas
thu
silico
approach
focus
defin
new
pharmacophor
featur
repres
target
structur
nucleophil
addit
ligand
crucial
step
proteas
inactiv
gener
hypothes
retriev
known
proteas
inhibitor
virtual
screen
cycl
propos
potenti
unconfirm
ligand
proteas
bind
site
avail
databas
viral
capsid
sever
hrv
elucid
crystal
resolut
hrv
coat
protein
complex
highli
activ
inhibitor
win
use
start
point
gener
structurebas
pharmacophor
model
model
use
virtual
screen
larg
commerci
avail
databas
final
select
virtual
hit
worth
subject
biolog
test
dock
studi
princip
compon
analysi
perform
six
candid
test
abil
inhibit
hrv
serotyp
multiplecycl
cpe
inhibit
assay
although
show
certain
antivir
potenti
one
longitudin
piperazin
deriv
inhibit
viru
concentr
mm
test
candid
show
difficulti
interpret
experiment
result
due
rel
high
cytotox
bad
solubl
circumst
ask
cautiou
estim
molecular
properti
compound
select
state
author
subsequ
perform
studi
best
valid
pharmacophor
model
use
identif
natur
deriv
hrv
coat
protein
inhibitor
virtual
screen
experi
inhous
gener
dio
use
describ
base
virtual
predict
ligand
consid
knowledg
tradit
use
sesquiterpen
umbelliferon
gum
resin
ferula
sp
ie
asafetida
final
select
promis
candid
biolog
evalu
antivir
activ
asafetida
isol
constitu
assess
exploratori
determin
inhibit
cpe
induc
hrv
serotyp
result
reveal
dosedepend
select
antihrv
activ
serotyp
asafetida
virtual
predict
constitu
farnesiferol
b
c
fig
tabl
iii
ic
mm
respect
scrutin
select
two
compound
comparison
test
serotyp
amino
acid
sequenc
align
sinc
amino
acid
residu
involv
ligand
bind
show
match
serotyp
experiment
determin
select
profil
could
explain
differ
bind
pocket
serotyp
align
howev
reflect
potenti
protein
flexibl
bind
might
differ
hrv
serotyp
addit
offtarget
effect
could
reason
observ
select
recent
perform
virtual
parallel
screen
approach
tri
identifi
potenti
target
human
patholog
relev
constitu
isol
identifi
medicin
plant
ruta
graveolen
use
screen
platform
piplin
pilot
includ
discoveri
studio
lowenergi
conform
identifi
molecul
r
graveolen
subject
parallel
screen
purpos
int
ligand
pharmacophor
model
collect
use
current
compris
model
cover
uniqu
pharmacolog
target
base
predict
ligandtarget
interact
author
focus
three
biolog
target
name
acetylcholinesteras
hrv
coat
protein
cannabinoid
receptor
type
virtual
hit
nonhit
assay
respect
target
critic
evalu
perform
targetfish
approach
besid
predict
bioactiv
determin
cpe
reveal
virtual
hit
arborinin
fig
tabl
iii
ic
mm
nonpredict
hit
fig
tabl
iii
ic
mm
activ
antihrv
constitu
could
shown
appli
silico
strategi
capac
catalyz
drug
discoveri
profoundli
diseas
molecular
target
molecular
ligand
well
defin
creat
reliabl
pharmacophor
model
hrv
promin
member
picornavirida
famili
infect
human
frequent
viru
infect
hrv
mainli
lead
upper
respiratori
diseas
common
cold
may
also
caus
sever
lower
respiratori
tract
disord
although
symptomolog
sever
common
cold
rel
mild
cours
diseas
selflimit
socioeconom
impact
tremend
term
recoup
lost
product
due
sick
leav
last
decad
number
antihrv
agent
differ
originsynthet
natur
compound
biolog
botan
nutritionalshav
discov
differ
concept
use
strategi
discoveri
either
start
phenomenolog
effect
eg
empir
knowledg
folk
medicin
targetbas
molecular
level
eg
icam
capsid
binder
hrv
proteas
inhibitor
outcom
reveal
potent
promis
activ
partli
evalu
manag
hrvinduc
common
cold
clinic
trial
mainli
sober
benefit
sinc
hrv
infect
lifethreaten
case
potenti
therapi
safe
effect
almost
unrecogniz
level
side
effect
precondit
render
search
antihrvag
high
challeng
endeavor
explain
antivir
agent
approv
prevent
treatment
hrvinfect
today
despit
signific
effort
moreov
high
variabl
rhinovirus
suggest
need
one
activ
principl
cover
differ
mode
action
effect
treatment
therefor
high
need
ongo
search
new
synthet
well
natur
compound
molecular
level
increas
knowledg
hrv
life
cycl
gene
protein
sequenc
combin
improv
technolog
field
experiment
comput
method
continu
enabl
insight
spectacular
world
hrv
fundament
research
virtual
screen
approach
qsar
pharmacophoreand
dockingbas
screen
cycl
comput
compound
design
applic
ration
base
gain
expertis
differ
disciplin
adequ
infrastructur
research
encourag
hope
discoveri
clinic
develop
effort
continu
search
agent
may
treat
prevent
annoy
common
cold
